



**Press release**  
May 19, 2020  
Gothenburg

## **XPS™ sold to a leading lung transplant clinic in Europe**

**The AKH University Hospital in Vienna, Austria, which is one of the top three largest lung transplant clinics in Europe, has purchased an XPS™. It is estimated that the installation of the XPS™ will take place at the beginning of June.**

The clinic in Vienna has more than 30 years' experience of lung transplantation and has a well-reputed lung transplant program for being a leader in the field of Ex Vivo Lung Perfusion (EVLP). Austria has the highest rate of lung transplants per million population (13.3) according to the Global Observatory on Donation and Transplantation. The Division of Thoracic Surgery in Vienna is a high volume lung transplant center with more than 100 transplantations per year.

The AKH University Hospital has previously performed EVLP with the manual method (without the XPS™) and for a period of time borrowed an XPS™. According to the Company's business model, the pricing strategy for capital goods, that is the EVLP machines LS™ and XPS™, is so designed that sales of capital goods do not have a significant financial impact on the Company. According to the Company's pricing strategy, future sales of STEEN Solution™ for use in the EVLP machines and accompanying single-use items are of financial significance for the Company.

"The company are especially pleased that the AKH University Hospital in Vienna has purchased an XPS™ since the clinic in Vienna is in the forefront of enlarging the use of donated lungs and has historically performed ground breaking science in this area," says Magnus Nilsson, CEO of XVIVO Perfusion.

May 19, 2020  
Gothenburg  
XVIVO Perfusion AB (publ)

For further information please contact:  
Christoffer Rosenblad, CFO, +46 735 192159, [christoffer.rosenblad@xvivoperfusion.com](mailto:christoffer.rosenblad@xvivoperfusion.com)  
Magnus Nilsson, CEO, +46 31 788 2150, [magnus.nilsson@xvivoperfusion.com](mailto:magnus.nilsson@xvivoperfusion.com)

---

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in the USA. The Xvivo share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website [www.xvivoperfusion.com](http://www.xvivoperfusion.com).

---

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.  
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.  
E-mail: [info@xvivoperfusion.com](mailto:info@xvivoperfusion.com). Website: [www.xvivoperfusion.com](http://www.xvivoperfusion.com)

The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CET on May 19, 2020.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.